Stay updated with breaking news from Looking Statements Phathom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research Phase 1 population PK data abstract concludes the
Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock FLORHAM PARK, N.J., Dec. 15, 2020 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, 2,250,000 shares of its common stock in an underwritten public offering. In addition, Phathom in...